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Summary
Objective
This study aims to investigate relations of serum leptin at age 4 with development of
adiposity and linear growth during 3 years of follow-up among 75 Greek children and
to identify serum metabolites associated with leptin at age 4 and to characterize their
associations with adiposity gain and linear growth.
Methods
Linear regression models that accounted for maternal age, education and gestational
weight gain and child’s age and sex were used to examine associations of leptin and
leptin-associated metabolites measured at age 4 with indicators of adiposity and linear
growth at age 7.
Results
Each 1-unit increment in natural log-(ln)-transformed leptin corresponded with 0.33 (95%
CI: 0.10, 0.55) units greater body mass index-for-age z-score gain during follow-up.
Likewise, higher levels of the leptin-associated metabolites methylmalonyl-carnitine
and glutaconyl-carnitine corresponded with 0.14 (95% CI: 0.01, 0.27) and 0.07 (95%
CI: 0.01, 0.16) units higher body mass index-for-age z-score gain, respectively. These
relationships did not differ by sex or baseline weight status and were independent of
linear growth.
Conclusions
These findings suggest that leptin, methylmalonyl-carnitine and possibly glutaconyl-
carnitine are associated with weight gain during early childhood. Future studies are
warranted to confirm these findings in other populations.
Keywords: metabolites, adiposity, children, leptin.
Abbreviations
BMIZ body mass index-for-age z-score
HAZ height-for-age z-score
SS subscapular skinfold
TR triceps skinfold
Introduction
Leptin, an adipocyte-derived hormone, is an important
regulator of weight and metabolism. Although high
circulating leptin is traditionally regarded as a conse-
quence of excess fat mass, elevated leptin can also pre-
cede weight gain. In adults, high leptin in conjunction
with overweight/obesity status suggests hypothalamic
resistance to leptin’s hunger-inhibiting effects (1), which
could lead to additional weight gain over time. Several
studies have also observed a direct relationship between
circulating leptin and subsequent weight gain after
adjusting for body size at baseline (2–4), suggesting that
leptin resistance can occur independently of weight sta-
tus. This relationship is less clear in children. Studies in
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paediatric populations indicate that both low (5,6) and
high (7–9) leptin are associated with weight gain over
time. Potential explanations for the discrepancies include
the possibility that young children may not yet have de-
veloped leptin resistance (10) and the fact that leptin has
pleiotropic effects on bone growth (11), which could con-
found the relationship between leptin and adiposity gain.
The overarching aim of this study was to investigate re-
lations of serum leptin at age 4 years with adiposity gain
and linear growth during 3 years of follow-up among 75
children. To improve understanding of biochemical path-
ways linking leptin to weight gain, a secondary aim was
to identify metabolites associated with leptin at baseline
and to explore their relations with adiposity and linear
growth during follow-up.
Our hypothesis was that higher leptin, as well as any
leptin-related metabolites, is associated with greater
gains in adiposity, as indicated by change in age-
standardized and sex-standardized body mass index
(BMI), the sum of the triceps and subscapular skinfold
thicknesses, % fat mass and waist circumference,
independently of linear growth. Results from this work will
enhance understanding of etiological pathways underly-
ing the accrual of excess fat mass during early life.
Methods
This study includes participants of the Rhea cohort in
Crete, Greece (12). The present analysis included 75 chil-
dren with data on anthropometry, serum leptin and
targeted metabolomics data at the 4-year research visit
(baseline) and anthropometry at the 7-year visit (follow-
up). All procedures were approved by the ethics commit-
tee of the University Hospital in Heraklion, Crete, Greece.
All participants provided written informed consent.
Anthropometry
At the 4-year visit, research assistants (RAs) measured
the children’s weight, height, waist circumference and
the subscapular (SS) and triceps (TR) skinfold thicknesses
(13). Body mass index-for-age (BMIZ) and height-for-age
(HAZ) z-scores were derived using the World Health Or-
ganization growth standard (14–16). Indicators of adipos-
ity included BMIZ, SS+TR, % fat calculated from
skinfolds using Slaughter’s equation (17) and waist cir-
cumference. At the 7-year visit, RAs measured anthro-
pometry and calculated the same anthropometric
indices. At this time, RAs also conducted bioelectrical im-
pedance assessments (BIA) of fat mass and % fat. Out-
comes of interest were change in each adiposity
indicator (BMIZ, SS+TR, Slaughter’s % fat and waist cir-
cumference) and linear growth (HAZ) between the 4- and
7-year visits. Attained BIA fat mass and % fat at 7 years
were also assessed, although it was not possible to cal-
culate change as BIA was only carried out at follow-up.
Serum leptin and targeted metabolomics
At the 4-year visit, RAs collected blood from the children,
from which serum leptin (ngmL1) was quantified (18).
Targeted metabolomics analyses were carried out on se-
rum to quantify amino acid and acylcarnitine species pre-
viously associated with childhood obesity and leptin (19)
using a mass spectrometry-based approach (Absolute
IDQ p180 kit, Biocrates Life Sciences AG, Austria). Me-
tabolite concentrations were adjusted for batch effects
and normalized as a z-score centred on the median and
scaled by the mean absolute deviation from the median.
Data analysis
The first step of the analysis was to examine associations
of leptin with background characteristics in order to iden-
tify potential confounders. Owing to non-normal distribu-
tions, leptin was natural log-(ln)-transformed prior to
regression analysis. The next step was to estimate
change in each adiposity indicator and HAZ with respect
to quartiles of leptin using linear regression. The associa-
tions were linear, so leptin was evaluated continuously. In
multivariable analysis, the models accounted for maternal
age, education and gestational weight gain (20) and
child’s age at the 4- and 7-year assessments and sex. In
all models for the adiposity outcomes, HAZ change was
also included as a covariate.
To identify metabolites associated with leptin, linear re-
gression models with leptin as the independent variable,
age and sex as covariates and individual metabolite z-
scores as the outcome were used. Metabolites were
retained for further analyses if the P-value for leptin’s β
was <0.05. Next, relations of each leptin-associated me-
tabolite with change in the anthropometric outcomes
were assessed using the same approach as for leptin.
In sensitivity analyses, maternal pre-pregnancy BMI,
birthweight-for-gestational-age and breastfeeding dura-
tion were included in the models; accounting for these
covariates did not change the results, thus they were
not included in the final models. Formal tests for statisti-
cal interactions with sex and baseline weight status were
carried out for all associations. All analyses were
performed using SAS 9.3 (Cary, NC, USA).
Results
Median age at baseline was 4.2 years (range 4.0–4.5);
57.3% were boys. Table 1 shows associations of leptin
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with background characteristics. All adiposity indicators
and HAZ were positively related to leptin at baseline.
In multivariable analysis, each increment in ln-leptin
corresponded with 0.33 (95% CI: 0.10, 0.55) units greater
BMIZ gain during follow-up. Similar associations were
observed for the other adiposity indicators, although the
confidence intervals contained the null. Leptin at 4 years
was positively associated with BIA fat mass and % fat
at 7 years (Table 2).
Of the 21 amino acids and 20 acylcarnitines quantified
from serum at the 4-year visit, two were associated with
leptin: glutanconyl-carnitine and methylmalonyl-carnitine
(Table S1); both were positively associated with BMIZ
gain as well as BIA fat mass and % fat at 7 years
(Table 2). Neither leptin nor the metabolites were related
to linear growth. Adjustment for HAZ change in models
for the adiposity outcomes attenuated effect sizes, al-
though the relations with BMIZ remained apparent. There
was no evidence of effect modification by sex or baseline
weight status.
Discussion
In this study of Greek children, higher leptin at age 4 was
associated with greater BMIZ gain during 3 years of
follow-up. Higher concentrations of the leptin-associated
metabolites methylmalonyl-carnitine and glutaconyl-
carnitine at baseline also corresponded with greater BMIZ
gain. These relations did not differ by sex or baseline
weight status and were independent of linear growth.
Our results add to current evidence in several ways.
First, most paediatric investigations of leptin and weight
gain were conducted in older children (>6 years at
Table 1 Distribution of serum leptin concentrations at baseline
(4 years) according to characteristics of 75 Rhea cohort mother–child
pairs
N*
Mean ± SD
P†Leptin (ngmL1)
Overall 75 2.34 ± 1.49
Family and perinatal characteristics
Mother’s age at enrollment (years) 0.23
20–24 4 2.08 ± 1.06
25–34 55 2.20 ± 1.43
35–43 14 2.73 ± 1.60
Mother’s education 0.82
Less than university 33 2.41 ± 1.80
University education 40 2.33 ± 1.22
Parity 0.91
Primiparous 30 2.33 ± 1.27
Muliparous 37 2.29 ± 1.61
Mother’s pre-pregnancy BMI (kg m2) 0.16
Normal weight (18.5–24.9) 51 2.05 ± 1.11
Overweight (25–29.9) 15 3.35 ± 2.18
Obese (≥30) 6 1.89 ± 0.31
Gestational weight gain‡ 0.13
Inadequate 16 2.43 ± 1.61
Adequate 33 2.60 ± 1.59
Excessive 23 1.81 ± 0.99
Birth size§ 0.94
SGA (<10th %tile) 6 2.36 ± 2.59
AGA (10–≤90th %tile) 63 2.33 ± 1.40
LGA (>90th %tile) 6 2.43 ± 1.33
Mother smoking habits 0.38
Never 49 2.47 ± 1.63
Former 12 1.84 ± 0.86
Smoked during pregnancy 8 2.18 ± 1.11
Duration of breastfeeding (months) 0.82
<6 55 1.27 ± 1.42
≥6 20 2.28 ± 1.60
Child characteristics at the 4-year research visit
Sex 0.03
Female 32 2.77 ± 1.79
Male 43 2.02 ± 1.14
BMI-for-age z-score¶ 0.0002
≤1 46 1.89 ± 1.14
>1 and ≤2 15 2.72 ± 1.57
>2 14 3.41 ± 1.85
SS + TR (mm) <0.0001
Tertile 1 (median = 12.5) 23 1.38 ± 0.68
Tertile 2 (median = 16.5) 24 2.30 ± 1.06
Tertile 3 (median = 21.4) 24 3.39 ± 1.84
Slaughter’s % fat <0.0001
Tertile 1 (median = 13.5) 23 1.33 ± 0.64
Tertile 2 (median = 19.0) 24 2.34 ± 1.04
Tertile 3 (median = 24.6) 24 3.39 ± 1.84
Waist circumference (cm) <0.0001
Tertile 1 (median = 50.0) 24 1.40 ± 0.72
Tertile 2 (median = 53.5) 24 2.35 ± 1.19
Tertile 3 (median = 57.2) 26 3.25 ± 1.74
Continues
Table 1. Continued
N*
Mean ± SD
P†Leptin (ng mL1)
Height-for-age z-score¶ 0.007
≤1 59 2.17 ± 1.30
>1 and ≤2 13 2.60 ± 1.38
>2 3 4.69 ± 3.46
*Totals may not add up to 75 because of missing values.
†Represents a test for linear trend with the exception of sex, smoking
habits and breastfeeding duration (Wald test).
‡According to the IOM 2009 gestational weight gain guidelines (12).
§Based on internally standardized percentile values as previously
described (4).
¶According to the World Health Organization growth reference (6–8).
For both BMI and height, the ‘<1 z-score’ category includes one
child with z-score <2.
AGA, appropriate for gestational age; BMI, body mass index; IOM,
Institute of Medicine; LGA, large for gestational age; SD, standard
deviation; SGA, small for gestational age; SS, subscapular; TR,
triceps.
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baseline) and have yielded both positive (7–10) and in-
verse associations (5,6). The discrepant literature could
be due to the influence of pubertal onset on the relation
between leptin and body composition (21). The positive
association observed between leptin and BMIZ gain
aligns with results from similarly aged children in the
USA (10) and suggests that leptin resistance may begin
early in the life course. Identification of specific
timeframes and opportunities to mitigate leptin resistance
is an area of ongoing human (10) and animal research
(22,23).
Second, the relation between leptin and BMIZ gain was
independent of HAZ change, suggesting that leptin stim-
ulates fat accretion rather than linear growth during early
childhood. However, because leptin was not associated
with change in the other adiposity indicators, the relation
with BMIZ may also reflect gains in lean mass that was
not accounted for by height change. Future studies
assessing change in directly measured body composition
(e.g. dual x-ray absorptiometry) are warranted to confirm
our findings.
Finally, despite the established link between leptin and
obesity (1), little is known of the underlying biochemical
pathways. Two leptin-associated metabolites were identi-
fied in the analysis, methylmalonyl-carnitine and
glutaconyl-carnitine, both of which also correlated with
BMIZ gain. Although the literature on glutaconyl-carnitine
is scant, elevated methylmalonyl-carnitine is a hallmark of
methylmalonic acidemia, a genetic defect in metabolism
of certain fats and proteins (24). Because leptin is in-
volved in hepatic lipid oxidation (25), the relationships
among leptin, methylmalonyl-carnitine and adiposity gain
may revolve around altered fatty acid metabolism. Specif-
ically, leptin resistance may lead to defective hepatic lipid
oxidation, which can lead to dysregulated satiety (26) and
weight gain (27). In this scenario, methylmalonyl-carnitine
is a marker of defective fatty acid metabolism rather than
a causal mechanism; whether methylmalonyl-carnitine
exerts independent pro-adipogenic effects deserves fur-
ther investigation.
Strengths of this study include the prospective design,
availability of blood specimens during early childhood
Table 2 Associations of leptin and two leptin-associated metabolites with adiposity and linear growth during follow-up
β (95% CI) for change in each anthropometric indicator
Mean ± SD
Leptin Methylmalonyl-carnitine Glutaconyl-carnitine
Per unit* Per z-score† Per z-score†
Δ Adiposity (7 years-4 years)
Δ BMI z-score 0.75 ± 0.92
Model 1 0.33 (0.10, 0.55) 0.14 (0.01, 0.27) 0.07 (-0.01, 0.16)
Model 2 0.25 (0.04, 0.45) 0.11 (0.00, 0.23) 0.09 (0.01, 0.16)
Δ SS + TR (mm) 1.19 ± 6.59
Model 1 1.41 (0.33, 3.17) 0.49 (0.53, 1.51) 0.08 (0.59, 0.74)
Model 2 1.14 (0.59, 2.88) 0.50 (0.50, 1.49) 0.18 (0.47, 0.83)
Δ Slaughter’s % fat 2.17 ± 5.15
Model 1 0.28 (1.14, 1.71) 0.19 (0.64, 1.01) 0.04 (0.49, 0.57)
Model 2 0.09 (1.34, 1.51) 0.19 (0.62, 1.00) 0.11 (0.42, 0.63)
Δ Waist circumference (cm) 4.88 ± 4.87
Model 1 0.72 (0.54, 1.99) 0.04 (0.78, 0.70) 0.23 (0.71, 0.24)
Model 2 0.39 (0.77, 1.55) 0.05 (0.71, 0.62) 0.12 (0.56, 0.31)
Linear growth (7 years-4 years)
Δ Height z-score 0.29 ± 0.37 0.06 (0.02, 0.14) 0.02 (0.03, 0.07) 0.01 (0.04, 0.02)
BIA measurements at 7 years
Fat mass (kg) 6.0 ± 3.0
Model 1 1.60 (0.85, 2.36) 0.52 (0.06, 0.98) 0.28 (0.02, 0.59)
Model 2 1.45 (0.71, 2.18) 0.47 (0.02, 0.91) 0.32 (0.03, 0.61)
% Fat 23.0 ± 6.6
Model 1 2.84 (1.09, 4.58) 0.48 (0.20, 1.17) 0.99 (0.04, 2.02)
Model 2 2.66 (0.91, 4.41) 0.92 (0.10, 1.94) 0.53 (0.15, 1.20)
Model 1: Adjusted for mother’s age, education and gestational weight gain (IOM 2009 categories) and child’s age and sex.
Model 2: Model 1 + change in height z-score.
*Natural log-(ln)-transformed for regression analysis.
†Each metabolite was centred at the median and scaled by the mean absolute distance from the median.
BIA, bioelectrical impedance assessments; BMI, body mass index; CI, confidence interval; IOM, Institute of Medicine; SS, subscapular; TR,
triceps.
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and added mechanistic insight via targeted metabolo-
mics data. Limitations include the non-fasting nature of
the blood draws and the relatively small sample size.
In conclusion, higher leptin, methylmalonyl-carnitine
and glutaconyl-carnitine at age 4 corresponded with
greater BMIZ gain between ages 4 and 7 years and higher
BIA fat mass at 7 years. The magnitude of associations,
particularly for leptin (0.33 higher BMIZ per unit ln-leptin),
may have implications at the population level. In a large
retrospective study of Danish adults, each unit of BMIZ
at age 7 corresponded with 10% and 7% higher risk of
fatal cardiovascular disease in men and women, respec-
tively (28). The risk increased linearly with age such that
it was twice as high by 13 years (28), emphasizing the
importance of identifying determinants of excess weight
gain as early as possible. Additional work is required to
confirm our findings and to identify modifiable determi-
nants of leptin during early life.
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